Immuron Ltd — Investor Presentation 2011

Sep 4, 2011

==> picture [229 x 73] intentionally omitted <==

Oral immunotherapy using antibodies

Joe Baini, CEO

5 September 2011

2011

CONFIDENTIAL – Immuron

1

==> picture [229 x 73] intentionally omitted <==

FORWARD LOOKING STATEMENT

This presentation and Immuron’s accompanying comments and explanations may include forward‐looking statements including statements containing words such as “ may ”, “ expect ”, “ believe ”, and “ intend ”, and may describe opinions about future events.

We have based these forward‐looking statements on information currently available to us and on our current intentions, beliefs, expectations and projections about future events.

These statements are not guarantees of future performance which involves a range of risks, such as risks relating to the development of new products, any of which may cause Immuron’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward‐looking statements.

2011

CONFIDENTIAL – Immuron

2

Table of Contents

==> picture [143 x 45] intentionally omitted <==

•Brief Company Overview Section I •Key Strategies and Targets Section II •The Roadmap Section III

2011

CONFIDENTIAL – Immuron

3

==> picture [229 x 73] intentionally omitted <==

Section I

COMPANY OVERVIEW

2011

CONFIDENTIAL – Immuron

4

About Immuron

==> picture [143 x 45] intentionally omitted <==

• Melbourne based, biopharmaceutical company (ASX: IMC)

• Market Cap~24M

• R&D at Hadassah Medical Center Israel, Uni. Melb. & Monash Uni.

• Focuses on Oral Immunotherapy using dairy‐derived antibodies

• Developed and patented a cost effective method to harvest polyclonal antibodies from hyper immune colostrum (HIC) of immunized cows

• Superior safety profile enables acceleration of product development

• • Strong pipeline

• First commercialized product – Travelan (travellers’ diarrhoea)

• Several clinical phase products & research and preclinical stage programs

• Addressing a broad range of indications in the infectious diseases, immune mediated diseases and oncology fields

2011

CONFIDENTIAL – Immuron

5

The Immuron Advantage

==> picture [143 x 45] intentionally omitted <==

==> picture [129 x 79] intentionally omitted <==

Oral Immunotherapy Using Antibodies

Oral immunotherapy using dairy‐derived polyclonal antibodies for metabolic & infectious diseases, oncology, and additional indications

==> picture [129 x 79] intentionally omitted <==

Strong Intellectual Property

Immuron owns 7 patent families that protect its product portfolio Immuron has also acquired over 12 years of “trade secrets”

==> picture [130 x 80] intentionally omitted <==

Strong Collaboration with Key Research Partners

Collaborations with leading research centres at Hadassah Medical Center, University of Melbourne & Monash University

==> picture [130 x 80] intentionally omitted <==

Key Alliance with Global Pharmaceutical Company

Aggressive distribution in place with new partners (including Nycomed) expected to play a key role in global commercialization

2011

CONFIDENTIAL – Immuron 6

==> picture [143 x 45] intentionally omitted <==

==> picture [694 x 313] intentionally omitted <==

----- Start of picture text -----

2010 2011 2012 2013
Travelan 1 [st] partner Consolidate/ 10+ Markets Significant
Expand Globally Revenue
INFLUENZA Mice/Ferrets End preclinical/ Consolidate trials/ Reg/Partners/
Commence Ph. 1 Commercial production Launch!
NASH Ph. 1/2a IND/Ph. 2b protocol Commence 2b/ License/
Seek partners Commence Ph. 3
----- End of picture text -----

2011

CONFIDENTIAL – Immuron

7

==> picture [229 x 73] intentionally omitted <==

Section II

KEY STRATEGIES AND TARGETS

2011

CONFIDENTIAL – Immuron

8

Adding Value/Decreasing Risk

==> picture [144 x 45] intentionally omitted <==

==> picture [721 x 454] intentionally omitted <==

----- Start of picture text -----

$/€
Commercial
Risk
Commercialisation
Development
Immuron Nycomed
Meda
New partners
Research
Hadassah
U Melbourne
Monash U
TIME
2011 CONFIDENTIAL – Immuron 9
COMMERCIAL VALUE
----- End of picture text -----

Product Pipeline

==> picture [143 x 45] intentionally omitted <==

Indication Research` Pre‐Clinical Phase I Phase II Phase III Market Traveller’s Diarrhea Metabolic Syndrome / NASH (IMM‐124E) Influenza (IMM‐255) 2013/14 Clostridium difficile infection HIV (IMM‐243 & IMM‐252) Hepatic Carcinoma Others

2011

CONFIDENTIAL – Immuron

10

Key Strategies

==> picture [143 x 45] intentionally omitted <==

I

• •Aggressively increase revenue through ramp-up of global partners/sales of Travelan

II

•Driving development of revolutionary influenza product ( IMM-255 ) towards a commercial-ready product in 2-3 years.

III

==> picture [71 x 101] intentionally omitted <==

----- Start of picture text -----

IV
----- End of picture text -----

• NASH : accelerating development & license opportunities. Significant unmet medical need. FDA pre-IND mtg June. Blockbuster potential

• •Leverage Hadassah, Uni of Melbourne & Monash Uni partnerships to progress products into clinical trials from pipeline

2011

CONFIDENTIAL – Immuron

11

==> picture [229 x 73] intentionally omitted <==

TRAVELAN ‐ MARKET EXPANSION

2011

CONFIDENTIAL – Immuron

12

Travellers’ Diarrhoea

==> picture [143 x 45] intentionally omitted <==

• Travellers’ Diarrhoea (TD) is the most common health condition facing travellers

• Research shows that up to 50% of people who travel to developing countries will develop the problem

• Typically characterized by stomach cramps, diarrhoea , fever and nausea

• The most common cause of this condition is Enterotoxigenic E. Coli ( ETEC ) bacteria

• Up to 70% of all cases of TD are caused by ETEC

==> picture [168 x 128] intentionally omitted <==

==> picture [168 x 128] intentionally omitted <==

==> picture [166 x 127] intentionally omitted <==

2011

CONFIDENTIAL – Immuron

13

Travelan – Immuron’s product in the market

==> picture [143 x 45] intentionally omitted <==

• Antibodies directed against bacteria that cause travellers’ diarrhoea

• TGA approved , sales in Australia

• Unique preventative oral immune therapeutic

• Seeking steep sales growth. Global market ~US$650m+ pa

• Exclusively licensed to Nycomed in Aust/NZ since Apr 2010

• Partnered with Meda Consumer Healthcare in the US

• Additional global markets being aggressively pursued

• Major territories aiming to launch 2012‐13

==> picture [204 x 150] intentionally omitted <==

2011

CONFIDENTIAL – Immuron

14

www.travelan.com.au

==> picture [625 x 460] intentionally omitted <==

2011 CONFIDENTIAL – Immuron

15

==> picture [229 x 73] intentionally omitted <==

INFLUENZA (IMM 255) – ACCELERATE:

==> picture [310 x 33] intentionally omitted <==

==> picture [63 x 16] intentionally omitted <==

----- Start of picture text -----

2013/14
----- End of picture text -----

CONFIDENTIAL – Immuron

2011

16

Influenza

==> picture [143 x 45] intentionally omitted <==

• Direct medical costs in US – $10.4B pa*

• 3‐5m cases pa of severe illness

• Over 500,000 deaths worldwide pa

• Influenza is the 8[th] leading cause of American deaths

==> picture [165 x 125] intentionally omitted <==

==> picture [166 x 125] intentionally omitted <==

==> picture [166 x 125] intentionally omitted <==

*Molinari et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs doi:10.1016/j.vaccine.2007.03.046

2011 CONFIDENTIAL – Immuron

17

IMM‐255 – Clinical Development Roadmap

==> picture [143 x 45] intentionally omitted <==

==> picture [546 x 122] intentionally omitted <==

----- Start of picture text -----

Initial trials were very effective in
identifying the protective action of
Immuron’s antibodies against infection by
the H1N1 human virus
----- End of picture text -----

==> picture [546 x 121] intentionally omitted <==

----- Start of picture text -----

Following the above positive results
additional ferret trials were approved
----- End of picture text -----

==> picture [558 x 122] intentionally omitted <==

----- Start of picture text -----

IMM‐255 to be developed for use in trials to
be developed as an oral formulation
----- End of picture text -----

2011

CONFIDENTIAL – Immuron

18

Revolutionizing the Treatment of Influenza

==> picture [143 x 45] intentionally omitted <==

IMM 255 is being designed as the world’s first dual‐acting and all‐natural oral : therapy that can both

+ Oral Antibody IMM 255 Colostrum Derived Adjuvants

==> picture [118 x 84] intentionally omitted <==

==> picture [122 x 85] intentionally omitted <==

Passive immunity, inhibiting the influenza infection

• Binds and inhibits influenza

• infection

Boosts the immune system to fight influenza

• Decrease of suppressor cells

• Augment anti influenza cellular immunity

Not viral strain specific – product alteration not needed annually

2011

CONFIDENTIAL – Immuron

19

IMM‐255 – Immuron’s Solution to Influenza

==> picture [143 x 45] intentionally omitted <==

==> picture [325 x 260] intentionally omitted <==

----- Start of picture text -----

Aiming for world’s first
dual‐acting orally
administered product;
mucosal protection
against influenza virus
and boosting immunity
against influenza
----- End of picture text -----

Antibodies designed to cope with the rapidly changing strains of flu as virus evolves (advantage of polyclonal antibodies)

==> picture [28 x 25] intentionally omitted <==

Convenience of an easily accessible OTC therapy – not requiring a doctor visit or prescription

==> picture [99 x 89] intentionally omitted <==

==> picture [28 x 25] intentionally omitted <==

Market size : unlike vaccines, usually reserved for the elderly and immune compromised, IMM 255’s potential market is the entire population

==> picture [100 x 89] intentionally omitted <==

==> picture [28 x 25] intentionally omitted <==

IMM 255 is safe

==> picture [28 x 25] intentionally omitted <==

IMM 255 is 100% natural

==> picture [28 x 25] intentionally omitted <==

IMM 255 is patent protected

2011

CONFIDENTIAL – Immuron

20

Commercial Strategy

==> picture [143 x 45] intentionally omitted <==

==> picture [672 x 249] intentionally omitted <==

----- Start of picture text -----

Q4 2011 Q4 2012 Q4 2013
Preparation of
Commercial
vaccine seed stock
production of anti‐
for commercial
influenza HIC
production
Carry out further
Carry out clinical
clinical trials (if Product Launch
trials
needed)
----- End of picture text -----

2011

CONFIDENTIAL – Immuron

21

==> picture [229 x 73] intentionally omitted <==

NASH (IMM‐124E) ‐ FILE IND

2011

CONFIDENTIAL – Immuron

22

NASH – a major epidemic of the 21[st] Century

==> picture [143 x 45] intentionally omitted <==

NCID predicts: Over 25m Americans will have NASH by 2025

==> picture [138 x 82] intentionally omitted <==

==> picture [138 x 81] intentionally omitted <==

==> picture [138 x 82] intentionally omitted <==

==> picture [138 x 82] intentionally omitted <==

NO approved treatment for NASH by either the FDA or the European Medicines Agency Demand for off‐label use, expected to be US$3.2bn at 2016 (however ineffective) Positive & encouraging results for phase 1/2a Clinical Trials

Immuron’s solution for NASH could be on the market in less than 4 years

2011

CONFIDENTIAL – Immuron

23

IMM‐124E – Immuron’s Solution for NASH

==> picture [143 x 45] intentionally omitted <==

Could be on the market in less than 4 years

==> picture [98 x 98] intentionally omitted <==

Orally administrated treatment Results to date very positive : Safe Trending of all parameters in the desirable direction Addresses inflammatory mechanism Pursuing commencement of Phase 2b clinical trials Intending to negotiate fast track development

2011

CONFIDENTIAL – Immuron

24

IMM‐124E – Highlights and Next Steps

==> picture [143 x 45] intentionally omitted <==

==> picture [514 x 89] intentionally omitted <==

----- Start of picture text -----

Immuron is developing a therapy for NASH utilizing
HIC IP
----- End of picture text -----

==> picture [514 x 89] intentionally omitted <==

----- Start of picture text -----

The therapy uses similar platform technology as
Travelan, incorporating the anti‐LPS antibodies
----- End of picture text -----

==> picture [515 x 89] intentionally omitted <==

----- Start of picture text -----

The plan is now to proceed to a Phase 2b trial and a
Phase 3 trial in 2013
----- End of picture text -----

==> picture [515 x 89] intentionally omitted <==

----- Start of picture text -----

Proposed that the Phase 2b trial will be conducted
over four sites in Israel, the US and Australia with
patients on treatment for three months
----- End of picture text -----

2011

CONFIDENTIAL – Immuron

25

==> picture [229 x 73] intentionally omitted <==

Section III

THE ROAD MAP

2011

CONFIDENTIAL – Immuron

26

Key Strategies

==> picture [143 x 45] intentionally omitted <==

I

• •Aggressively increase revenue through ramp-up of global partners/sales of Travelan

II

•Driving development of revolutionary influenza product ( IMM-255 ) towards a commercial-ready product in 2-3 years.

III

==> picture [71 x 101] intentionally omitted <==

----- Start of picture text -----

IV
----- End of picture text -----

• NASH : accelerating development & license opportunities. Serious unmet medical need. FDA pre-IND mtg June. Blockbuster potential

• •Leverage Hadassah, University of Melbourne & Monash Uni partnerships to progress products into clinical trials from pipeline

2011

CONFIDENTIAL – Immuron

27

==> picture [143 x 45] intentionally omitted <==

==> picture [694 x 313] intentionally omitted <==

----- Start of picture text -----

2010 2011 2012 2013
Travelan 1 [st] partner Consolidate/ 10+ Markets Significant
Expand Globally Revenue
INFLUENZA Mice/Ferrets End preclinical/ Consolidate trials/ Reg/Partners/
Commence Ph. 1 Commercial production Launch!
NASH Ph. 1/2a IND/Ph. 2b protocol Commence 2b/ License/
Seek partners Commence Ph. 3
----- End of picture text -----

2011

CONFIDENTIAL – Immuron

28

Immuron’s Leadership: Management

==> picture [143 x 45] intentionally omitted <==

Joe Baini , CEO

• Experienced biotechnology executive; former GM for Gilead Sciences & non‐exec chairman for Avexa Ltd

Dr Grant Rawlin , Chief Scientific Officer

• Registered veterinary surgeon ; extensive experience in regulatory affairs and R&D

Mr Graeme Stevens , Chief Financial Officer & Company Secretary

• Qualified Chartered Accountant ; more than 30 years professional experience with large & small companies

Prof Yaron Ilan , Medical Director

• Directo r, Dept of Medicine, Hadassah Medical Center ‐ Hebrew University, Jerusalem. Scientist /clinician in internal medicine, immunology, liver diseases

Mr Amos Meltzer , VP Business Development

• Experienced life sciences technology commercialisation specialist , a scientist & lawyer , formerly with Compugen Ltd

Mr Brian Muller , Manager Regulatory Affairs

• Experienced scientist with commercial focus; more than 20 years R&D experience in Australian biotechnology companies

Dr. Nina Webster , Director Commercialisation & IP

• Successful biotech and pharmaceutical executive formerly with Acrux

2011

CONFIDENTIAL – Immuron

29

Immuron’s Leadership: Board

==> picture [143 x 45] intentionally omitted <==

Prof. Colin Chapman , Chairman

• Professional Fellow at the Australian Health Workforce Institute, University of Melbourne . Key role in establishment of Acrux . Emeritus professor and Immediate past Dean, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University

Prof. Roy Robins‐Browne , Non‐executive Director

• Professor & Head , Dept of Microbiology & Immunology, the University of Melbourne ; Joint Head , Infectious Diseases & Microbiology Research Group, Murdoch Children’s Research Institute , Royal Children’s Hospital, Melbourne

Dr Elane Zelcer , Non‐executive Director

• Executive Director, BioConsult Pty Ltd. Experienced start‐up CEO ; executive, board and advisory roles in private sector, universities, CRCs, State & Federal government committees

Mr Simon Sallka , Non‐executive Director

• Executive Director & Chief Investment Officer, Falcon Capital Pty Ltd; more than 25 years funds management experience as portfolio manager

2011

CONFIDENTIAL – Immuron

30

Summary

==> picture [161 x 109] intentionally omitted <==

==> picture [162 x 111] intentionally omitted <==

Thank You

www.immuron.com

==> picture [143 x 45] intentionally omitted <==

www.travelan.com.au

2011

CONFIDENTIAL – Immuron

31